SCHEMBL31358711

SCHEMBL31358711

Cc1ccc([N+](=O)[O-])cc1-c1ccc(C=C2C(=O)c3ccccc3C2=O)o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
KMT2A Q03164 5/20 0.64
POLB P06746 5/20 0.64
L3MBTL1 Q9Y468 5/20 0.64
MEN1 O00255 4/20 0.64
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 3/20 0.64
CTDSP1 Q9GZU7 2/20 0.64
PPM1G O15355 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPN7 P35236 1/20 0.55
PTPN5 P54829 1/20 0.55
PTPRO Q16827 1/20 0.55
PTPN22 Q9Y2R2 1/20 0.55
MET P08581 1/20 0.52
EGFR P00533 1/20 0.52
PKM P14618 3/20 0.51
MAPK1 P28482 1/20 0.51
LMNA P02545 2/20 0.50
RECQL P46063 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358883 0.86 GSK3A (0.59) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358742 0.85 KMT2A (0.49) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358808 0.84 KMT2A (0.57) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358735 0.84 KMT2A (0.57) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358799 0.84 KMT2A (0.66) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358762 0.84 PIK3CG (0.60) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358851 0.83 KMT2A (0.59) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358800 0.82 KMT2A (0.60) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL11968680 0.81 HTRA2 (0.68) MAPTKMT2APOLBL3MBTL1MEN1
SCHEMBL31358774 0.81 BRAF (0.67) MAPTKMT2APOLBL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 MAPT 4688/4885KMT2A 1043/4885POLB 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.